



Contract Amendment:

Priority Healthcare Distribution d/b/a Curascript Specialty Distribution - Procurement of Specialty Drugs

BOS Budget & Finance Committee

David Smith, PharmD, Chief Pharmacy Officer, SFDPH

December 3, 2025

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH



Overview of Item

Priority Healthcare Distribution, Inc. d/b/a CuraScript Specialty Distribution – Procurement of Specialty Drugs

- **Contract Amendment Amount:** \$89,480,168
 - **Not-to-Exceed Amount:** \$98,480,168
- **Timeline:** December 1, 2023 – November 30, 2030
- **Contractor:** Priority Healthcare Distribution, d/b/a CuraScript Specialty Distribution
- **Previous contract details:**
 - 2022: Office of Contract Administration (OCA) approved sole source Original Waiver
 - 2025: OCA approved First Modification



Overview of Item

- **Specialty medications supplied by Curascript:**
 - Buprenorphine LAI (long-acting injectables including Brixadi, Sublocade) for Medications for Opioid Use Disorder (MOUD)
 - Nexplanon implant for long-acting birth control
 - Various medications for pulmonary arterial hypertension
- **Current contract status:** Contract authority is risking ability to buy LAI in this fiscal year after December 2025
- **Goal of contract amendment:** Obtain contract authority to align with City priorities for treatment of Substance Use Disorder (SUD)
- **SFDPH receives reimbursements from insurance for medications**



Conclusion

**DPH respectfully requests approval of this item.
Thank you!**